Identifying Potential Drug Targets for The EFCAB2 Protein (G84288)

Target Name: EFCAB2

NCBI ID: G84288

EFCAB2

Identifying Potential Drug Targets for The EFCAB2 Protein

The EFCAB2 (FLJ33608) protein is a member of the evolutionarily conserved EFcN-G module, which is a conserved family of proteins involved in various cellular processes. EFCAB2 is expressed in many tissues and organs, including brain, heart, and gastrointestinal tract, and has been implicated in several biological processes, including cell signaling, cell division, and tissue repair.

Drug Targeting

EFCAB2 has been identified as a potential drug target due to its unique structure and its involvement in various signaling pathways. One of the key advantages of EFCAB2 is its unique farnesylated cysteine 鈥嬧?媟esidue, which is rare in proteins. This cysteine 鈥嬧?媟esidue is involved in the regulation of cellular processes, including cell signaling and protein stability.

Additionally, EFCAB2 has been shown to play a role in several signaling pathways that are important for various cellular processes, including cell proliferation, apoptosis, and tissue repair. For example, EFCAB2 has been shown to be involved in the regulation of the TGF-β pathway, which is a well-established pathway involved in cell proliferation and tissue development.

Another signaling pathway that is relevant to EFCAB2 is the PI3K/AKT signaling pathway. This pathway is involved in the regulation of cellular processes that are important for survival and growth, including cell survival, angiogenesis, and inflammation.

EFCAB2 has also been shown to play a role in the regulation of cellular processes that are important for tissue repair and regeneration. For example, EFCAB2 has been shown to be involved in the regulation of cell proliferation and cell death in response to tissue damage, which is important for the repair and regeneration of damaged tissue.

Biomarker Potential

EFCAB2 has also been shown to have potential as a biomarker for several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, EFCAB2 has been shown to be involved in the regulation of cellular processes that are important for the development and progression of cancer, including the regulation of cell cycle progression and the regulation of apoptosis.

EFCAB2 has also been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, which is thought to be caused by the build-up of toxic protein aggregates. EFCAB2 has been shown to play a role in the regulation of the formation of these aggregates, which may be a potential therapeutic target for these conditions.

In addition to its potential as a biomarker, EFCAB2 also has implications as a drug target. The unique structure of EFCAB2, as well as its involvement in multiple signaling pathways, makes it an attractive target for small molecules. Several small molecules have been shown to interact with EFCAB2 and to have potential as a therapeutic agent for various diseases.

Conclusion

EFCAB2 is a unique protein that has been identified as a potential drug target due to its unique structure and its involvement in multiple signaling pathways. Its role in the regulation of cell signaling, cell division, and tissue repair makes it an attractive target for small molecules . Additionally, its involvement in the regulation of various biological processes makes it a potential biomarker for several diseases. Further research is needed to fully understand the role of EFCAB2 in cellular processes and its potential as a therapeutic agent.

Protein Name: EF-hand Calcium Binding Domain 2

Functions: Component of the nexin-dynein regulatory complex (N-DRC), a key regulator of ciliary/flagellar motility which maintains the alignment and integrity of the distal axoneme and regulates microtubule sliding in motile axonemes

The "EFCAB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EFCAB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets